시장보고서

상품코드

2008726

OTC 인공눈물 시장 보고서 : 제품 유형별, 용기 유형별, 제제별, 용도별, 유통 채널별, 지역별(2026-2034년)

OTC Artificial Tears Market Report by Product, Container Type, Formulation, Application, Distribution Channel, and Region 2026-2034

발행일: 2026년 04월 | 리서치사: 구분자

IMARC | 페이지 정보: 영문 137 Pages | 배송안내 : 2-3일 (영업일 기준)

가격

PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트 등의 Copy&Paste도 불가능합니다.

US $ 3,999

￦ 6,000,000

PDF & Excel (5 User License)

PDF & Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy&Paste가 불가능합니다. 인쇄는 5부까지 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,999

￦ 7,500,000

PDF & Excel (Corporate License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy&Paste가 가능합니다. 인쇄 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,999

￦ 9,000,000

※ 부가세 별도

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 OTC 인공눈물 시장 규모는 2025년에 57억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 82억 달러에 달하며, 2026-2034년에 CAGR 4.05%로 성장할 것으로 예측하고 있습니다.

일반의약품(OTC) 인공눈물은 눈의 윤활, 눈의 통증, 불편감, 작열감, 충혈, 충혈, 충혈, 충혈, 자극 완화에 사용되는 점안제입니다. 이들은 덱스트런, 글리세린, 프로필렌글리콜, 하이드록시프로필 메틸셀룰로오스(HPMC), 카복시메틸셀룰로오스를 사용하여 제조됩니다. 인공눈물은 결막, 각막 또는 안구 표면 전체에 충분한 수분과 윤활이 공급되지 않는 안구건조증 치료에 널리 사용되고 있습니다. OTC 인공눈물은 생체적합성이 있으며, 눈물막 안정화, 치유 촉진, 눈물 증발 억제에 도움이 됩니다. 또한 OTC 인공눈물은 연고, 스프레이, 유액, 용액, 젤 등의 형태로도 출시되어 사용 편의성이 매우 높은 것이 특징입니다.

OTC 인공눈물 시장 동향:

만성 안질환에 취약한 고령 인구의 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. 안구건조증(DES), 당뇨병, 영양결핍의 유병률이 증가함에 따라 눈의 불편함을 즉각적으로 완화시켜주는 OTC 인공눈물에 대한 수요가 증가하고 있습니다. 또한 스마트폰, TV(TV), 노트북 등 전자기기 사용이 증가하면서 과도한 화면 시청시간과 눈의 피로로 이어지고 있는 것도 OTC 인공눈물의 보급에 긍정적인 영향을 미치고 있습니다. 눈 깜빡임으로 활성화되는 코팅을 적용한 제품 개발 등 다양한 제품 혁신이 시장 성장을 촉진하고 있습니다. 이 코팅은 증발성 안구건조증 환자에게 눈의 보습 효과를 제공합니다. 이에 따라 각막에 산소 공급을 촉진하고 안구 표면의 건조를 방지하기 위한 콘택트렌즈와의 병용이 널리 보급되고 있는 것도 시장 성장을 촉진하고 있습니다. 기타, 특히 도시 지역의 대기오염 악화, 일반인들의 건강 의식 증가 등의 요인도 시장 성장을 촉진할 것으로 예상됩니다.

Over the Counter (OTC) artificial tears are eye drops that are used for lubricating eyes and providing relief from pain, discomfort, burning, redness, photophobia and irritation in the eyes. They are manufactured using dextran, glycerin, propylene glycol, hydroxypropyl methylcellulose (HPMC) and carboxymethylcellulose. Artificial tears are widely used for the treatment of dry eyes, which is a medical condition when sufficient moisture or lubrication is not generated on the conjunctiva, cornea or entire surface of the eye. OTC artificial tears are biocompatible and aid in stabilizing the tear film, promoting healing and minimizing tear evaporation. In addition to this, OTC artificial tears are also available in ointment, spray, emulsion, solution and gel forms that are highly convenient use.

OTC ARTIFICIAL TEARS MARKET TRENDS:

The rising geriatric population that is prone to chronic eye-related disorders is one of the key factors driving the growth of the market. Due to the increasing prevalence of dry eye syndrome (DES), diabetes and nutritional deficiencies, there is a rising demand for OTC artificial tears to provide immediate relief from discomfort in the eyes. Additionally, the increasing utilization of electronics, such as smartphones, televisions (TVs) and laptops, leading to excessive screen time and eye fatigue, is positively impacting the adoption of OTC artificial tears. Various product innovations, such as the development of variants fortified with blink-activated coatings, are providing a thrust to the market growth. These coatings provide ocular hydration to patients suffering from evaporative dry eye syndrome. In line with this, the widespread product adoption with contact lenses to facilitate the flow of oxygen to the cornea and prevent dryness on the surface of the eyes is favoring the market growth. Other factors, including rising levels of pollution, especially in the urban regions, along with the increasing health consciousness among the masses, are anticipated to drive the market toward growth.

KEY MARKET SEGMENTATION:

Breakup by Product:

Solution
Ointment
Emulsion
Gel
Spray Solution
Suspensions

Breakup by Container Type:

Plastic Single Dose Container
Plastic Multi-Dose Container
Others

Breakup by Formulation:

Preservative Based
Non-Preservative Based

Breakup by Application:

Dry Eye Syndrome
Allergies
Infections
UV and Blue Light Protection
Contact Lens Moisture Retention
Others

Breakup by Distribution Channel:

Hospital Pharmacies
Drug Store and Retail Pharmacies
Online Pharmacies

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

COMPETITIVE LANDSCAPE:

The report provides a comprehensive analysis of the competitive landscape in the global OTC artificial tears market with detailed profiles of all major companies, including:

AbbVie Inc.
Alcon
Bausch and Lamb
Jawa Pharmaceuticals Pvt. Ltd.
OASIS Medical, Inc.
OcuSoft
Rohto Eye Drops
Scope Ophthalmics Ltd.
Sentiss Pharma Pvt. Ltd.
Thea Pharmaceuticals Limited
Ursapharm Arzneimittel GmbH

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global OTC artificial tears market in 2025?

2. What is the expected growth rate of the global OTC artificial tears market during 2026-2034?

3. What are the key factors driving the global OTC artificial tears market?

4. What has been the impact of COVID-19 on the global OTC artificial tears market?

5. What is the breakup of the global OTC artificial tears market based on the product?

6. What is the breakup of the global OTC artificial tears market based on the container type?

7. What is the breakup of the global OTC artificial tears market based on formulation?

8. What is the breakup of the global OTC artificial tears market based on the application?

9. What is the breakup of the global OTC artificial tears market based on the distribution channel?

10. What are the key regions in the global OTC artificial tears market?

11. Who are the key players/companies in the global OTC artificial tears market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global OTC Artificial Tears Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product

6.1 Solution
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Ointment
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Emulsion
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Gel
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Spray Solution
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Suspensions
- 6.6.1 Market Trends
- 6.6.2 Market Forecast

7 Market Breakup by Container Type

7.1 Plastic Single Dose Container
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Plastic Multi-Dose Container
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast

8 Market Breakup by Formulation

8.1 Preservative Based
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Non-Preservative Based
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by Application

9.1 Dry Eye Syndrome
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Allergies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Infections
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 UV and Blue Light Protection
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
9.5 Contact Lens Moisture Retention
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
9.6 Others
- 9.6.1 Market Trends
- 9.6.2 Market Forecast

10 Market Breakup by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Drug Store and Retail Pharmacies
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Online Pharmacies
- 10.3.1 Market Trends
- 10.3.2 Market Forecast

11 Market Breakup by Region

11.1 North America
- 11.1.1 United States
  - 11.1.1.1 Market Trends
  - 11.1.1.2 Market Forecast
- 11.1.2 Canada
  - 11.1.2.1 Market Trends
  - 11.1.2.2 Market Forecast
11.2 Asia-Pacific
- 11.2.1 China
  - 11.2.1.1 Market Trends
  - 11.2.1.2 Market Forecast
- 11.2.2 Japan
  - 11.2.2.1 Market Trends
  - 11.2.2.2 Market Forecast
- 11.2.3 India
  - 11.2.3.1 Market Trends
  - 11.2.3.2 Market Forecast
- 11.2.4 South Korea
  - 11.2.4.1 Market Trends
  - 11.2.4.2 Market Forecast
- 11.2.5 Australia
  - 11.2.5.1 Market Trends
  - 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
  - 11.2.6.1 Market Trends
  - 11.2.6.2 Market Forecast
- 11.2.7 Others
  - 11.2.7.1 Market Trends
  - 11.2.7.2 Market Forecast
11.3 Europe
- 11.3.1 Germany
  - 11.3.1.1 Market Trends
  - 11.3.1.2 Market Forecast
- 11.3.2 France
  - 11.3.2.1 Market Trends
  - 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
  - 11.3.3.1 Market Trends
  - 11.3.3.2 Market Forecast
- 11.3.4 Italy
  - 11.3.4.1 Market Trends
  - 11.3.4.2 Market Forecast
- 11.3.5 Spain
  - 11.3.5.1 Market Trends
  - 11.3.5.2 Market Forecast
- 11.3.6 Russia
  - 11.3.6.1 Market Trends
  - 11.3.6.2 Market Forecast
- 11.3.7 Others
  - 11.3.7.1 Market Trends
  - 11.3.7.2 Market Forecast
11.4 Latin America
- 11.4.1 Brazil
  - 11.4.1.1 Market Trends
  - 11.4.1.2 Market Forecast
- 11.4.2 Mexico
  - 11.4.2.1 Market Trends
  - 11.4.2.2 Market Forecast
- 11.4.3 Others
  - 11.4.3.1 Market Trends
  - 11.4.3.2 Market Forecast
11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast

12 SWOT Analysis

12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
- 16.3.1 AbbVie Inc.
  - 16.3.1.1 Company Overview
  - 16.3.1.2 Product Portfolio
  - 16.3.1.3 Financials
  - 16.3.1.4 SWOT Analysis
- 16.3.2 Alcon
  - 16.3.2.1 Company Overview
  - 16.3.2.2 Product Portfolio
  - 16.3.2.3 Financials
- 16.3.3 Bausch and Lamb
  - 16.3.3.1 Company Overview
  - 16.3.3.2 Product Portfolio
  - 16.3.3.3 Financials
  - 16.3.3.4 SWOT Analysis
- 16.3.4 Jawa Pharmaceuticals Pvt. Ltd.
  - 16.3.4.1 Company Overview
  - 16.3.4.2 Product Portfolio
  - 16.3.4.3 Financials
  - 16.3.4.4 SWOT Analysis
- 16.3.5 OASIS Medical, Inc.
  - 16.3.5.1 Company Overview
  - 16.3.5.2 Product Portfolio
- 16.3.6 OcuSoft
  - 16.3.6.1 Company Overview
  - 16.3.6.2 Product Portfolio
- 16.3.7 Rohto Eye Drops
  - 16.3.7.1 Company Overview
  - 16.3.7.2 Product Portfolio
  - 16.3.7.3 Financials
  - 16.3.7.4 SWOT Analysis
- 16.3.8 Scope Ophthalmics Ltd.
  - 16.3.8.1 Company Overview
  - 16.3.8.2 Product Portfolio
  - 16.3.8.3 Financials
  - 16.3.8.4 SWOT Analysis
- 16.3.9 Sentiss Pharma Pvt. Ltd.
  - 16.3.9.1 Company Overview
  - 16.3.9.2 Product Portfolio
  - 16.3.9.3 Financials
  - 16.3.9.4 SWOT Analysis
- 16.3.10 Thea Pharmaceuticals Limited
  - 16.3.10.1 Company Overview
  - 16.3.10.2 Product Portfolio
  - 16.3.10.3 Financials
  - 16.3.10.4 SWOT Analysis
- 16.3.11 Ursapharm Arzneimittel GmbH
  - 16.3.11.1 Company Overview
  - 16.3.11.2 Product Portfolio